The FDA's recent decision to shut down operations of cheaper compounded versions of weight-loss drugs comes as the agency declares that shortages of popular medications like Wegovy and Zepbound are over. Many patients turned to compounders due to the high prices associated with brand-name drugs, which cost around $500 per month. This crackdown will raise treatment costs significantly for hundreds of thousands who relied on affordable alternatives, and the enforcement of this decision remains uncertain as deadlines loom for producers.
The FDA has ordered producers of cheaper compounded weight-loss drugs to cease operations, as it declares that shortages of brand-name drugs Wegovy and Zepbound have ended.
Patients will lose access to these affordable compounded medications, leading to a rise in costs for those seeking weight-loss treatments amidst this industry crackdown.
Collection
[
|
...
]